FDA Form 483 – Esperion Therapeutics Inc (Samer Kazziha, MD)

FDA Form 483 – Esperion Therapeutics Inc (Samer Kazziha, MD)

Regular price $89.00 USD
Regular price Sale price $89.00 USD
Sale Sold out
Original Request: Request 483 information for Samer Kazziha, MD, Cardiovascular Consultants, PC Esperion Therapeutics Inc, Protocol # 1002-043 Title of Project: A randomized double-blind, placebo-controlled study to assess the effects of Bempedoic Acid (ETC=1002) on the occurrence of major cardiovasular events in patient with, or at high risk for, cardiovascular disease who are statin intolerant. Thank you.
  • Status: Pending Fast-Track Request
  • Delivery: Approximately 1 to 2 weeks when the FOIA office is operating at regular capacity

NOTE: This document is not currently in our library. Upon purchase, we will request the document from the FDA FOIA office. Learn more about Fast-Track Requests here.

View full details